Leishmania eukaryotic initiation factor 4A (LeIF) (LeIF)

Leishmania eukaryotic initiation factor 4A (LeIF) is a member of the DEAD-box family of RNA helicases and is a critical component of the translation initiation machinery in Leishmania parasites. It functions as an ATP-dependent RNA helicase that unwinds the 5' untranslated region of mRNA, allowing the 40S ribosomal subunit to scan for the start codon. In addition to its essential role in parasite protein synthesis, LeIF is recognized as a potent Th1-type immunostimulatory protein, inducing the production of cytokines like IL-12 and IFN-gamma in host macrophages and dendritic cells. This dual role makes it both a promising target for small-molecule inhibitors and a key candidate for vaccine development, often used as an adjuvant or part of polyprotein vaccines. As a therapeutic target, its ATPase and helicase activities are targeted by inhibitors such as 6-aminocholestanol and various synthetic compounds to disrupt parasite viability. However, the high structural similarity between the parasite LeIF and human eIF4A necessitates the development of highly selective inhibitors to avoid off-target effects in the host. Research continues to focus on identifying unique binding pockets in the parasite enzyme to improve drug specificity and efficacy against visceral and cutaneous leishmaniasis.

Other names

Leishmania elongation initiation factorLeishmania elongation and initiation factorEukaryotic initiation factor 4ALieIFLbeIFDEAD-box protein

Inhibition of ATPase and RNA helicase activity, which prevents the formation of the eIF4F translation initiation complex and halts protein synthesis.